Anti-cyclic citrullinated peptide antibody predicts the development of rheumatoid arthritis in patients with undifferentiated arthritis.

Autor:	Li C; Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China., Zhang Y; Department of Rheumatology and Immunology, Beijing Jishuitan Hospital, Beijing 100035, China., Song H; Department of Rheumatology and Immunology, Beijing Jishuitan Hospital, Beijing 100035, China., Gao J; Department of Rheumatology and Immunology, Changhai Hospital, Shanghai 200433, China., Zhao DB; Department of Rheumatology and Immunology, Changhai Hospital, Shanghai 200433, China., Zhu Q; Department of Rheumatology, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 200052, China., He DY; Department of Rheumatology, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 200052, China., Wang L; Department of Rheumatology and Immunology, Anhui Provincial Hospital, Hefei, Anhui 230001, China., Li XP; Department of Rheumatology and Immunology, Anhui Provincial Hospital, Hefei, Anhui 230001, China., Liu XD; Department of Rheumatology and Immunology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China., Xiao WG; Department of Rheumatology and Immunology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China., Wu XY; Department of Rheumatology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China., Wu HX; Department of Rheumatology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China., Tu W; Department of Rheumatology and Immunology, Tongji Hospital, Wuhan, Hubei 430030, China., Hu SX; Department of Rheumatology and Immunology, Tongji Hospital, Wuhan, Hubei 430030, China., Wang X; Department of Rheumatology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China., Li ZJ; Department of Rheumatology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China., Lu ZM; Department of Rheumatology and Immunology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China., Da ZY; Department of Rheumatology and Immunology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China., Liang B; Department of Rheumatology and Immunology, The Hospital of Shunyi District Beijing, Beijing 101300, China., Liu XM; Department of Rheumatology and Immunology, The Hospital of Shunyi District Beijing, Beijing 101300, China., Zhao JW; Department of Infection and Immunology, Tianjin Union Medical Center, Tianjin 300121, China., Li L; Department of Infection and Immunology, Tianjin Union Medical Center, Tianjin 300121, China., Han F; Department of Rheumatology and Immunology, Tianjin First Central Hospital, Tianjin 300192, China., Qi WF; Department of Rheumatology and Immunology, Tianjin First Central Hospital, Tianjin 300192, China., Wei W; Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin 300052, China., Ma X; Department of Rheumatology and Immunology, Peace Hospital, Shijiazhuang, Hebei 050000, China., Li ZB; Department of Rheumatology and Immunology, Peace Hospital, Shijiazhuang, Hebei 050000, China., Zheng GM; Department of Rheumatology and Immunology, Hebei General Hospital, Shijiazhuang, Hebei 050051, China., Zhang FX; Department of Rheumatology and Immunology, Hebei General Hospital, Shijiazhuang, Hebei 050051, China., Li Y; Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, Jiangxi 330006, China., Wang YL; Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, Jiangxi 330006, China., Ling GH; Division of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China., Chen JW; Division of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China., Hou XQ; Department of Rheumatology and Immunology, The First College of Clinical Medical Science of China Three Gorges University & Yichang Central People's Hospital, Yichang, Hubei 443003, China., Zhang J; Department of Rheumatology and Immunology I Wald, Xi'an No. 5 Hospital, Xi'an, Shaanxi 710082, China., Chen QP; Department of Rheumatology and Immunology I Wald, Xi'an No. 5 Hospital, Xi'an, Shaanxi 710082, China., Liu CL; Department of Rheumatology and Immunology V Wald, Xi'an No. 5 Hospital, Xi'an, Shaanxi 710082, China., Zhang Y; Department of Nephrology and Rheumatology, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550004, China., Zeng JS; Department of Nephrology and Rheumatology, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550004, China., Zou QH; Department of Rheumatology, The First Hospital Affiliated to AMU (Southwest Hospital), Chongqing 400038, China., Fang YF; Department of Rheumatology, The First Hospital Affiliated to AMU (Southwest Hospital), Chongqing 400038, China., Su Y; Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China., Li ZG; Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.
Jazyk:	angličtina
Zdroj:	Chinese medical journal [Chin Med J (Engl)] 2019 Dec 20; Vol. 132 (24), pp. 2899-2904.
DOI:	10.1097/CM9.0000000000000570
Abstrakt:	Background: Clinical outcomes of undifferentiated arthritis (UA) are diverse, and only 40% of patients with UA develop rheumatoid arthritis (RA) after 3 years. Discovering predictive markers at disease onset for further intervention is critical. Therefore, our objective was to analyze the clinical outcomes of UA and ascertain the predictors for RA development. Methods: We performed a prospective, multi-center study from January 2013 to October 2016 among Chinese patients diagnosed with UA in 22 tertiary-care hospitals. Clinical and serological parameters were obtained at recruitment. Follow-up was undertaken in all patients every 12 weeks for 2 years. Predictive factors of disease progression were identified using multivariate Cox proportional hazards regression. Results: A total of 234 patients were recruited in this study, and 17 (7.3%) patients failed to follow up during the study. Among the 217 patients who completed the study, 83 (38.2%) patients went into remission. UA patients who developed RA had a higher rheumatoid factor (RF)-positivity (42.9% vs. 16.8%, χ = 8.228, P = 0.008), anti-cyclic citrullinated peptide (CCP) antibody-positivity (66.7% vs. 10.7%, χ = 43.897, P < 0.001), and double-positivity rate of RF and anti-CCP antibody (38.1% vs. 4.1%, χ = 32.131, P < 0.001) than those who did not. Anti-CCP antibody but not RF was an independent predictor for RA development (hazard ratio 18.017, 95% confidence interval: 5.803-55.938; P < 0.001). Conclusion: As an independent predictor of RA, anti-CCP antibody should be tested at disease onset in all patients with UA.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu